<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114363">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01971567</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00024763</org_study_id>
    <nct_id>NCT01971567</nct_id>
  </id_info>
  <brief_title>High-resolution, Relational, Resonance-based, Electroencephalic Mirroring (HIRREM) to Relieve Insomnia</brief_title>
  <official_title>High-resolution, Relational, Resonance-based, Electroencephalic Mirroring (HIRREM) to Relieve Insomnia: A Randomized, Placebo-Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the addition of High-resolution,
      relational, resonance-based, electroencephalic mirroring (HIRREM) to usual care will improve
      insomnia symptoms based on changes in the Insomnia Severity Index at two months following
      completion of the intervention, compared to placebo plus usual care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insomnia is the most prevalent sleep disorder and is associated with significant
      psychosocial and somatic pathology.  Effective noninvasive interventions for insomnia are
      lacking.  High-resolution, relational, resonance-based, electroencephalic mirroring
      (HIRREM), is a noninvasive, brain feedback technology to facilitate relaxation and
      auto-calibration of neural oscillations by using auditory tones to reflect brain frequencies
      in near real time.  An open label, randomized, crossover pilot trial showed that HIRREM was
      safe and effective, with significant benefits for individuals with moderate to severe
      insomnia, based on differential change with symptoms of insomnia (Insomnia Severity Index,
      ISI).  This study will extend those results in a larger cohort using a single blind, placebo
      controlled study design.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Insomnia Severity Index (ISI)</measure>
    <time_frame>8-10 weeks after completion of the intervention</time_frame>
    <safety_issue>No</safety_issue>
    <description>The ISI is a 7 question, self-reported measure to evaluate symptoms of insomnia, with responses from 0-4 for each question, yielding scores ranging from 0-28.  The ISI will be collected at enrollment (pre-intervention), and at 1-7 days, 8-10 weeks, and 16-18 weeks after completion of the intervention.  The primary outcome will be change from enrollment to 8-10 weeks after completion of the intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daily sleep diary</measure>
    <time_frame>Collected from the enrollment visit through completion of the primary data collection visit, 8-10 weeks after completion of the intervention</time_frame>
    <safety_issue>No</safety_issue>
    <description>This ten item instrument will be an online daily sleep diary to evaluate the amount and quality of sleep.  This allows evaluation of the timing and trajectory of any improvements in sleep, including appreciation of the presence and duration of placebo effects.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Beck Depression Inventory - II (BDI-II)</measure>
    <time_frame>8-10 weeks after completion of the intervention</time_frame>
    <safety_issue>No</safety_issue>
    <description>Depression will be measured by the Beck Depression Inventory-II (BDI-II) which will be collected at enrollment (pre-intervention), and at 1-7 days, 8-10 weeks, and 16-18 weeks after completion of the intervention.  The BDI-II is a 21-item questionnaire with response values of 0-3 for each item, yielding scores ranging from 0-63.</description>
  </other_outcome>
  <other_outcome>
    <measure>Beck Anxiety Inventory (BAI)</measure>
    <time_frame>8-10 weeks after completion of the intervention</time_frame>
    <safety_issue>No</safety_issue>
    <description>Anxiety will be measured by the Beck Anxiety Inventory (BAI), which will be completed at the enrollment visit (pre-intervention), as well as 1-7 days, 8-10 weeks, and 16-18 weeks after completion of the intervention.  The BAI is a 21-item questionnaire with response values from 0-3 for each item, yielding scores ranging from 0-63.</description>
  </other_outcome>
  <other_outcome>
    <measure>EQ-5D</measure>
    <time_frame>8-10 weeks after completion of the intervention</time_frame>
    <safety_issue>No</safety_issue>
    <description>Health-related quality of life will be measured by the EQ-5D, which will be collected at the enrollment visit, as well as 1-7 days, 8-10, and 16-18 weeks after completion of the intervention.  The EQ-5D consists of 5 items assessing an individual's current health status (values from 0-2), yielding scores ranging from 0-10.  Overall health status is also assessed with values from 0-100.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>HIRREM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM) is a novel, noninvasive, electroencephalic-based feedback technology to facilitate relaxation and auto-calibration of neural oscillations by using auditory tones to reflect brain frequencies in near real time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in this arm will receive a sham-HIRREM placebo, for which the scalp sensors have no active recording capability, and for which the auditory tonal feedback is randomly generated rather than based on current brain frequencies and amplitudes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HIRREM</intervention_name>
    <arm_group_label>HIRREM</arm_group_label>
    <other_name>High-resolution, relational, resonance-based, electroencephalic mirroring</other_name>
    <other_name>Brainwave Optimization</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe clinical insomnia (Insomnia Severity Index score of 15 or higher)

        Exclusion Criteria:

          -  Unable, unwilling, or incompetent to provide informed consent

          -  Physically unable to come to the study visits

          -  Known obstructive sleep apnea

          -  Diagnosed periodic limb movement disorder or known restless legs syndrome

          -  Known seizure disorder

          -  Known urinary problem (i.e. benign prostatic hypertrophy) which is the likely cause
             of the sleep disturbance

          -  Severe hearing impairment

          -  Known, or suspected diagnosis of post-traumatic stress disorder (PTSD)

          -  Known, relevant traumatic brain injury (TBI)

          -  Ongoing need for treatment with opiate, benzodiazepine, or anti-psychotic
             medications, anti-depressant medications such as SSRI, SNRI, or tricyclics, and sleep
             medications such as zolpidem or eszopiclone

          -  Anticipated and ongoing use of recreational drugs or alcohol

          -  Lack of internet or smart phone access
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles H Tegeler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, Wake Forest School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lilana Hines</last_name>
    <phone>336-716-9447</phone>
    <email>lhines@wakehealth.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Debbie Singleton</last_name>
    <phone>336-716-9482</phone>
    <email>dsinglet@wakehealth.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurology, Wake Forest School of Medicine</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nancy Buchheimer</last_name>
      <phone>336-716-3961</phone>
      <email>nbuchhe@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Charles H Tegeler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandhya R Kumar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine L Tegeler, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jared F Cook, MA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicholas M Pajewski, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hossam A Shaltout, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gerdes L, Gerdes P, Lee SW, H Tegeler C. HIRREMâ„¢: a noninvasive, allostatic methodology for relaxation and auto-calibration of neural oscillations. Brain Behav. 2013 Mar;3(2):193-205. doi: 10.1002/brb3.116. Epub 2013 Jan 14.</citation>
    <PMID>23532171</PMID>
  </reference>
  <reference>
    <citation>Tegeler CH, Kumar SR, Conklin D, Lee SW, Gerdes L, Turner DP, Tegeler CL, C Fidali B, Houle TT. Open label, randomized, crossover pilot trial of high-resolution, relational, resonance-based, electroencephalic mirroring to relieve insomnia. Brain Behav. 2012 Nov;2(6):814-24. doi: 10.1002/brb3.101. Epub 2012 Oct 28.</citation>
    <PMID>23170244</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 23, 2013</lastchanged_date>
  <firstreceived_date>October 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wake Forest School of Medicine</investigator_affiliation>
    <investigator_full_name>Charles Tegeler</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Insomnia</keyword>
  <keyword>Electroencephalic</keyword>
  <keyword>Biofeedback</keyword>
  <keyword>Neural oscillations</keyword>
  <keyword>Auto calibration</keyword>
  <keyword>Relaxation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
